Cargando…

Ontogeny-related pharmacogene changes in the pediatric liver transcriptome

OBJECTIVES: The majority of drug dosing studies are based on adult populations, with modification of the dosing for children based on size and weight. This rudimentary approach for drug dosing children is limited, as biologically a child can differ from an adult in far more aspects than just size an...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Richard, Bi, Chengpeng, Gaedigk, Roger, Heruth, Daniel P., Ye, Shui Qing, Leeder, J. Steven, Fridley, Brooke L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805126/
https://www.ncbi.nlm.nih.gov/pubmed/29360682
http://dx.doi.org/10.1097/FPC.0000000000000326
_version_ 1783298913497776128
author Meier, Richard
Bi, Chengpeng
Gaedigk, Roger
Heruth, Daniel P.
Ye, Shui Qing
Leeder, J. Steven
Fridley, Brooke L.
author_facet Meier, Richard
Bi, Chengpeng
Gaedigk, Roger
Heruth, Daniel P.
Ye, Shui Qing
Leeder, J. Steven
Fridley, Brooke L.
author_sort Meier, Richard
collection PubMed
description OBJECTIVES: The majority of drug dosing studies are based on adult populations, with modification of the dosing for children based on size and weight. This rudimentary approach for drug dosing children is limited, as biologically a child can differ from an adult in far more aspects than just size and weight. Specifically, understanding the ontogeny of childhood liver development is critical in dosing drugs that are metabolized through the liver, as the rate of metabolism determines the duration and intensity of a drug’s pharmacologic action. Therefore, we set out to determine pharmacogenes that change over childhood development, followed by a secondary agnostic analysis, assessing changes transcriptome wide. MATERIALS AND METHODS: A total of 47 human liver tissue samples, with between 10 and 13 samples in four age groups spanning childhood development, underwent pair-end sequencing. Kruskal–Wallis and Spearman’s rank correlation tests were used to determine the association of gene expression levels with age. Gene set analysis based on the pathways in KEGG utilized the gamma method. Correction for multiple testing was completed using q-values. RESULTS: We found evidence for increased expression of ‘very important pharmacogenes’, for example, coagulation factor V (F5) (P=6.7×10(−7)), angiotensin I converting enzyme (ACE) (P=6.4×10(−3)), and solute carrier family 22 member 1 (SLC22A1) (P=7.0×10(−5)) over childhood development. In contrast, we observed a significant decrease in expression of two alternative CYP3A7 transcripts (P=1.5×10(−5) and 3.0×10(−5)) over development. The analysis of genome-wide changes detected transcripts in the following genes with significant changes in mRNA expression (P<1×10(−9) with false discovery rate<5×0(−5)): ADCY1, PTPRD, CNDP1, DCAF12L1 and HIP1. Gene set analysis determined ontogeny-related transcriptomic changes in the renin–angiotensin pathway (P<0.002), with lower expression of the pathway, in general, observed in liver samples from younger participants. CONCLUSION: Considering that the renin–angiotensin pathway plays a central role in blood pressure and plasma sodium concentration, and our observation that ACE and PTPRD expression increased over the spectrum of childhood development, this finding could potentially impact the dosing of an entire class of drugs known as ACE-inhibitors in pediatric patients.
format Online
Article
Text
id pubmed-5805126
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-58051262018-02-13 Ontogeny-related pharmacogene changes in the pediatric liver transcriptome Meier, Richard Bi, Chengpeng Gaedigk, Roger Heruth, Daniel P. Ye, Shui Qing Leeder, J. Steven Fridley, Brooke L. Pharmacogenet Genomics Original Articles OBJECTIVES: The majority of drug dosing studies are based on adult populations, with modification of the dosing for children based on size and weight. This rudimentary approach for drug dosing children is limited, as biologically a child can differ from an adult in far more aspects than just size and weight. Specifically, understanding the ontogeny of childhood liver development is critical in dosing drugs that are metabolized through the liver, as the rate of metabolism determines the duration and intensity of a drug’s pharmacologic action. Therefore, we set out to determine pharmacogenes that change over childhood development, followed by a secondary agnostic analysis, assessing changes transcriptome wide. MATERIALS AND METHODS: A total of 47 human liver tissue samples, with between 10 and 13 samples in four age groups spanning childhood development, underwent pair-end sequencing. Kruskal–Wallis and Spearman’s rank correlation tests were used to determine the association of gene expression levels with age. Gene set analysis based on the pathways in KEGG utilized the gamma method. Correction for multiple testing was completed using q-values. RESULTS: We found evidence for increased expression of ‘very important pharmacogenes’, for example, coagulation factor V (F5) (P=6.7×10(−7)), angiotensin I converting enzyme (ACE) (P=6.4×10(−3)), and solute carrier family 22 member 1 (SLC22A1) (P=7.0×10(−5)) over childhood development. In contrast, we observed a significant decrease in expression of two alternative CYP3A7 transcripts (P=1.5×10(−5) and 3.0×10(−5)) over development. The analysis of genome-wide changes detected transcripts in the following genes with significant changes in mRNA expression (P<1×10(−9) with false discovery rate<5×0(−5)): ADCY1, PTPRD, CNDP1, DCAF12L1 and HIP1. Gene set analysis determined ontogeny-related transcriptomic changes in the renin–angiotensin pathway (P<0.002), with lower expression of the pathway, in general, observed in liver samples from younger participants. CONCLUSION: Considering that the renin–angiotensin pathway plays a central role in blood pressure and plasma sodium concentration, and our observation that ACE and PTPRD expression increased over the spectrum of childhood development, this finding could potentially impact the dosing of an entire class of drugs known as ACE-inhibitors in pediatric patients. Lippincott Williams & Wilkins 2018-03 2017-12-14 /pmc/articles/PMC5805126/ /pubmed/29360682 http://dx.doi.org/10.1097/FPC.0000000000000326 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Articles
Meier, Richard
Bi, Chengpeng
Gaedigk, Roger
Heruth, Daniel P.
Ye, Shui Qing
Leeder, J. Steven
Fridley, Brooke L.
Ontogeny-related pharmacogene changes in the pediatric liver transcriptome
title Ontogeny-related pharmacogene changes in the pediatric liver transcriptome
title_full Ontogeny-related pharmacogene changes in the pediatric liver transcriptome
title_fullStr Ontogeny-related pharmacogene changes in the pediatric liver transcriptome
title_full_unstemmed Ontogeny-related pharmacogene changes in the pediatric liver transcriptome
title_short Ontogeny-related pharmacogene changes in the pediatric liver transcriptome
title_sort ontogeny-related pharmacogene changes in the pediatric liver transcriptome
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805126/
https://www.ncbi.nlm.nih.gov/pubmed/29360682
http://dx.doi.org/10.1097/FPC.0000000000000326
work_keys_str_mv AT meierrichard ontogenyrelatedpharmacogenechangesinthepediatriclivertranscriptome
AT bichengpeng ontogenyrelatedpharmacogenechangesinthepediatriclivertranscriptome
AT gaedigkroger ontogenyrelatedpharmacogenechangesinthepediatriclivertranscriptome
AT heruthdanielp ontogenyrelatedpharmacogenechangesinthepediatriclivertranscriptome
AT yeshuiqing ontogenyrelatedpharmacogenechangesinthepediatriclivertranscriptome
AT leederjsteven ontogenyrelatedpharmacogenechangesinthepediatriclivertranscriptome
AT fridleybrookel ontogenyrelatedpharmacogenechangesinthepediatriclivertranscriptome